|
NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #7776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IV B or Recurrent Endometrial Cancer
NRG-GY018 is now closed to accrual.
Patients entered to Step 1 prior to study closure will be able to proceed to Step 2.
| 
